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Abstract
Purpose: As cancer control strategies have become more successful, issues around survival have become increasingly
important to researchers and policy makers. The aim of this study was to examine the role of a range of clinical and socio-
demographic variables in explaining variations in survival after a prostate cancer diagnosis, paying particular attention to
the role of healthcare provider(s) i.e. private versus public status.
Methods: Data were extracted from the National Cancer Registry Ireland, for patients diagnosed with prostate cancer from
1998–2009 (N= 26,183). A series of multivariate Cox and logistic regression models were used to examine the role of
healthcare provider and socio-economic status (area-based deprivation) on survival, controlling for age, stage, Gleason
grade, marital status and region of residence. Survival was based on all-cause mortality.
Results: Older individuals who were treated in a private care setting were more likely to have survived than those who had
not, when other factors were controlled for. Differences were evident with respect to marital status, region of residence,
clinical stage and Gleason grade. The effect of socio-economic status was modified by healthcare provider, such that risk of
death was higher in those men of lower socio-economic status treated by public, but not private providers in the Cox
models. The logistic models revealed a socio-economic gradient in risk of death overall; the gradient was larger for those
treated by public providers compared to those treated by private providers when controlling for a range of other
confounding factors.
Conclusion: The role of healthcare provider and socio-economic status in survival of men with prostate cancer may give rise
to concerns that warrant further investigation.
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Introduction
As cancer control strategies become more successful, issues
around survivorship have begun to receive more attention from
researchers and policy makers. Identifying variations in survivor-
ship and seeking to explain these among cancer patients has
attracted particular attention [1–3]. The incidence and survival
rates in prostate cancer offers a greater opportunity to examine
variations in survival compared with other cancers. Prostate
cancer is now the most commonly diagnosed cancer in men in
developed countries [4]. Survival prospects for men are good: the
mean European age and area-standardised 5-year survival for men
diagnosed in 1995–99 was 76% and the 5-year relative survival in
the Republic of Ireland (RoI) was 88% for patients diagnosed in
2004-07 [5–6]. In the USA, prostate cancer survivors comprise an
estimated 43% of male cancer survivors [7] and large numbers of
men survive over relatively long periods of time [8].
In the RoI, approximately 2,500 men are diagnosed annually
with prostate cancer [9]. The RoI was estimated to have the
highest incidence of prostate cancer across Europe in 2006 and
2008 and the fifth highest prostate cancer mortality rate in Europe
[10–12]. Previous studies have highlighted the role of non-need
factors, namely voluntary private health insurance, in the uptake
of PSA testing in the RoI and across Europe [13–14]. Within this
context the examination of survival with respect to prostate cancer
in Ireland is opportune. The aim of this study was to examine what
role, if any, location of care i.e. public versus private, for prostate
cancer had on all-cause survival, controlling for a range of clinical
and socio-demographic variables.
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Materials and Methods
Study setting
The RoI has a mixed public-private healthcare system. All
citizens are entitled to the standard level of care within the public
system with some co-payments (including prescription charges and
General Practitioner (GP) charges for those above a given level of
income). Approximately one third of the population are entitled to
free health care services and medicines under the Health Service
Executive (HSE) General Medical Services (GMS) scheme based
on income and/or age criteria [15]. During the period of this
study, approximately half of the population held private health
insurance (PHI), with insurance plans which mainly cover the costs
of in-patient stays and outpatient visits; PHI is perceived by many
to provide speedier access to care [16]. There are 51 public
hospitals in the country, including 8 designated cancer centres;
however, cancer patients are also treated outside these cancer
centres [17]. Many of the public hospitals contain some private
beds, which patients with PHI may choose to use. There are also a
growing number of private hospitals (n = 24), some of which
undertake cancer surgery and/or provide radiotherapy [17].
Approximately 83% of total acute public hospital discharges
(N= 1,332,680 excluding maternity) in 2011 were categorised as
being treated on a public basis [18]. In 2004, the government set
up a statutory body, the National Treatment Purchase Fund
(NTPF), to alleviate the long waiting lists for public patients; the
NTPF monitors public patients and purchases treatment for those
who have been on waiting lists for over three months from private
hospitals [19]. The proportion of public patients treated in a
private setting under this initiative is small; in 2010 the total in-
patient services carried out under the NTPF was 24,118 (,2% of
overall total discharges), with urology and radiology accounting for
on average 11% of all NTPF procedures [20]. Therefore, the
majority of patients treated in a public setting do not obtain
private health care, suggesting they do not hold private insurance,
and the majority of patients treated in a private setting appear to
do so based on the possession of PHI.
Data
The NCR has permission under the Health (Provision of
Information) Act 1997 to collect and hold data on all persons
diagnosed with cancer in Ireland. The use of that data for research
is covered by the Statutory Instrument which established the
Registry Board in 1991. All datasets were anonymised prior to
analysis. Data were extracted from the National Cancer Registry
Ireland (NCRI), for all patients diagnosed with prostate cancer
(ICD10 C61) during 1998–2009 inclusive (N=26,938). Men with
incomplete records in relation to age (n = 18), clinical staging
(n = 8), county of residence (n = 9) and those diagnosed through
autopsy (n = 87), were excluded (total n = 122). The remaining
patients (n = 26,816) were stratified into three age-groups, 35 to 54
years, 55 to 69 years and $70 years, based on those used in the
European Randomised Study of Screening for Prostate Cancer
(ERSPC) and previous analyses [13–14,21]. Five socio-economic
groups were constructed using a national, standardised, area-based
measure of deprivation for patients’ place of residence at diagnosis
with ‘SES1’ being the highest and ‘SES5’ the lowest socio-
economic grouping [22–23]. A sixth group, ‘SESunk’ was
constructed for those who were unclassified i.e. patients whose
addresses were insufficiently precise to be able to allocate them to a
deprivation category (n = 2,771). Cases were also classified
according to the province of residence (of which there are four
in the RoI). Patients were classified according to whether or not
they were married or living as such at diagnosis and a binary
variable for smoking status was constructed reflecting whether or
not the man was a smoker at the time of diagnosis based on
medical record information recorded at the time of registration.
In terms of clinical variables, cases were grouped according to
the way in which they presented i.e. opportunistic ‘‘screening,’’
incidental (discovery during the course of another investigation or
treatment including Transurethral Resection of the Prostate
(TURP)), symptomatic, and ‘other’. Data was available on
Gleason grade and clinical and pathological classification TNM.
Gleason scores range from 2 to 10 and four categories were
constructed: grade 1, Gleason grade ,5; grade 2, Gleason grade
5–7; grade 3, Gleason grade .7 and grade 4- undifferentiated
tumour grade; a binary variable for grade unknown was also
constructed [24]. In keeping with clinical guidelines, each prostate
cancer was characterised in terms of summary stage, in five
categories (stage I–IV, and unknown) [25]. Additional analyses
revealed that the majority of patients with unknown grade and
stage were over 70 years and received treatment similar to those
with late stage prostate cancer (data not shown); therefore
assuming a hierarchical ordering, this suggests stage unknown is
similar to stage 4 and grade unknown is similar to grade 4;
individual survival estimates supports this assumption.
A variable classifying patients according to the likelihood of
public/private status of their prostate cancer healthcare provider(s)
was constructed as follows. Each hospital at which a patient is seen
in the first year following diagnosis is recorded by the NCRI. Since
it was not possible to identify the type of bed (i.e. public or private),
occupied by a patient in a public hospital, for this analysis ‘‘public’’
patients were defined as those who attended only public hospitals
during the first year of their treatment. In the same manner, those
who used only private facilities for their treatment were classified
as ‘‘private’’ patients. A third group, those who received part of
their care privately was also constructed. These categories can be
thought of as representing the observed counterpart of the
unobserved variable i.e. likelihood of being a private patient.
Patients treated publicly only being likely to be public patients,
those treated partly in the public and partly in the private system
being less likely to be public patients and those treated solely in the
private sector being unlikely to be public patients.
Deaths in those diagnosed with cancer are identified by the
NCRI by routine linkage with death certificates. For this study,
information on deaths was complete until 31/12/2010 (thus, all
patients had at least one year follow-up). Deaths from all-causes
were considered; information on cause-of-death is not generally
publicly available at the level of the individual. All data used in our
analyses are available from the National Cancer Registry Ireland
with standard terms and conditions for data release, use and
reporting. Further information about this is available from the
Registry website (http://www.ncri.ie/content/conditions-use-
national-cancer-registry-data).
Analysis
Survival time was calculated in months, from date of diagnosis,
with censoring applied for varying follow-up periods: (i) the entire
follow-up period available (i.e. to 31/12/2010); (ii) 3-year (36
months) follow-up; and (iii) 7-year (84 months) follow-up.
The impact of socio-economic status and healthcare provider(s)
i.e. private versus public, on survival was examined in three ways;
the three approaches were used for confirmatory purposes as well
as for purposes of exposition. Firstly, a series of Cox proportional
hazards models were run exploring the role of healthcare provider
alone (i.e. unadjusted for socio-demographic and clinical con-
founders) by year of diagnosis. The assumptions, strengths and
weaknesses of employing a Cox proportional hazards regression
Inequalities in Prostate Cancer Survival: A Population Based Study
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model for survival analysis in cancer have been extensively
discussed elsewhere [26–27]. One limitation of the conventional
Cox model is that the results are valid and interpretable only when
hazards are proportional over time. Non-proportional hazards
were evident in this data with respect to socio-economic status in
particular. Thus in our second approach, a series of stratified, Cox
non-proportional hazards models were run examining socio-
economic status controlling for a range of covariates including
healthcare provider, using a conditional approach [28]. Categor-
ical variables for socio-economic status were tested for joint
significance using Wald tests and Global tests were employed for
each Cox regression model to measure model appropriateness.
Thirdly, a series of logistic models were undertaken; in these
models the outcome of interest was a binary variable for vital
status – alive or dead. These models assessed the impact of a wider
range of demographic and clinical explanatory variables, including
Table 1. Characteristics of prostate cancer cases diagnosed from 1998–20091, included in analysis.
Variable Name
Number of
observations Variable Name
Number of
observations
Health provider: Public 18683 (70%) Marital status: Married 17715 (66%)
Private/Mixed 8133 (30%) Single/Divorced/Widowed/Unknown 9101 (34%)
Socio-economic status: SES1 4756 (18%) MOP2: Other 6338 (24%)
SES2 3138 (12%) Screen- opportunistic 4105 (15%)
SES3 3657 (14%) Incidental 2854 (11%)
SES4 4708 (18%) Symptomatic 13519 (50%)
SES5 7786 (29%) Smoker at diagnosis: No 23129 (86%)
SES Unk 2771 (9%) Yes 3687 (14%)
Stage: Stage I 872 (3%) Province: Leinster 12434 (46%)
Stage II 14009 (52%) Ulster 7958 (30%)
Stage III 2252 (8%) Connacht 4406 (16%)
Stage IV 3111 (12%) Munster 2018 (8%)
Stage Unknown 6572 (25%) Age: 35–54 years 1579 (6%)
Grade: Gleason ,5 1932 (7%) 55–69 years 12224 (45%)
Gleason 5–7 14324 (53%) 70 years and over 13013 (49%)
Gleason .7 5131 (19%)
Undifferentiated 85 (,1%)
Grade Unknown 5344 (20%)
1.) 26,938 diagnosed in 1998–2009 but (n = 122) excluded from analysis due to missing data.
2.) MOP- method of presentation.
3.) SES Unk- Socio-economic status unknown.
doi:10.1371/journal.pone.0106456.t001
Figure 1. Crude hazard ratios for healthcare provider by year of diagnosis for men diagnosed with prostate cancer (1998–2009). a.
This graph contains 12 individual Cox PH models where the base category is ‘Public Payer’ for varying follow-up periods up to 31/12/10. b. All Hazard
Ratios presented are statistically significant and confidence intervals are depicted by the line segments. c The test of proportional hazards (global
test) revealed marginal non-proportionality for models with the following year of diagnosis: 1998, 2002, 2003, 2004; therefore caution is warranted in
interpretation; however overall men with access to private healthcare had a lower risk of death than those who did not have access.
doi:10.1371/journal.pone.0106456.g001
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interactions, on risk of death; thus providing impacts of a wider
range of contributory factors on survival in a confirmatory manner
albeit not addressing time dependency on covariates. Wald tests
for clinical variables (i.e. grade and stage) and for demographics
(e.g. region of residence) and socio-economic status were
performed, while models were clustered by year of incidence
and logistic post estimation techniques including classification
competency and the Hosmer-Lemeshow goodness of fit statistic
were also calculated [29].
Results
26,816 men diagnosed with prostate cancer from 1998 to 2009
were included in the analysis. For the analysis based on 3-years
follow-up, 79% of men (16,116 of the 20,507 men diagnosed in
1998–2007) survived for 36 months or longer. For the analysis
based on 7 years follow-up, 55% of men (5,634 of the 10,310
diagnosed from 1998–2003) survived for 84 months or longer.
Table 1 details descriptive statistics for the entire study population.
Those treated solely in a public healthcare setting accounted for
70% (n= 18,683) of those diagnosed and the remaining 30%
(n= 8,133) were classified as receiving private care in part or
wholly during their treatment pathway: 17% (n= 4,465) were
treated solely in a private setting and 13% (n= 3,668) received
care in both public and private settings.
Crude hazard ratios for a series of Cox proportional hazard
regression models examining the impact of healthcare provider on
all-cause mortality by year of diagnosis are illustrated in Figure 1;
these are shown only for the entire follow-up period available (i.e.
to 31/12/2010). The hazard ratio fluctuated by year of diagnosis
and on average, those who were seen or treated at any time in the
first year post-diagnosis in a private healthcare setting had a
statistically significant reduced risk of death compared to those
seen or treated solely in a public setting (univariate HR 0.43 (95%
CI: 0.41, 0.45)).
Table 2. Multivariate stratified Cox regression for 36 month survival.
Stratified interaction non-PH Cox regression Model (36 month follow-up)
Private Public Married Not Married
SES1 1 1 1 1
SES2 1.02 1.19*** 1.34*** 1.09
SES3 0.95 1.01 1.10 1.03
SES4 1.00 1.16** 1.31*** 1.08
SES5 1.05 1.21*** 1.43*** 1.15**
SES Unknown 0.85 1.15** 1.14 1.15
Global Test 8.22 (P = 0.14) 4.88 (P = 0.43) 7.09 (P = 0.21) 8.88 (P = 0.11)
Wald Test *SES group Chi2(5) = 2.02 (P = 0.85) Chi2(5) = 21.31 (P = 0.00) Chi2(5) = 42.67 (P = 0.00) Chi2(5) = 5.54 (P = 0.35)
Number of Observations 6191 14316 13929 6578
Gleason grade 5–7 Gleason grade .7 Stage II Stage III
SES1 1 1 1 1
SES2 1.46*** 1.16 1.58*** 1.23
SES3 1.20** 1.05 1.24* 0.94
SES4 1.29** 1.20** 1.40*** 1.02
SES5 1.58*** 1.24*** 1.51*** 1.46*
SES Unknown 1.36*** 1.19 1.35** 0.98
Global Test 6.98 (P = 0.22) 4.36 (P = 0.50) 12.03 (P = 0.04) 6.07 (P = 0.29)
Wald Test *SES group Chi2(5) = 29.24 (P = 0.00) Chi2(5) = 9.01 (P = 0.10) Chi2(5) = 23.50 (P = 0.00) Chi2(5) = 6.08 (P = 0.30)
Number of Observations 11105 3881 10306 1690
Leinster Connacht Munster Ulster
SES1 1 1 1 1
SES2 1.41*** 1.21 1.00 0.75
SES3 1.16* 0.90 1.00 0.95
SES4 1.29*** 1.27* 1.00 1.03
SES5 1.59*** 1.17 1.17* 0.79
SES Unknown 1.30*** 1.10 1.03 0.60
Global Test 5.18 (P = 0.39) 9.89 (P = 0.08) 4.09 (P = 0.54) 3.88 (P = 0.57)
Wald Test *SES group Chi2(5) = 55.04 (P = 0.00) Chi2(5) = 9.39 (P = 0.09) Chi2(5) = 7.50 (P = 0.19) Chi2(5) = 7.03 (P = 0.22)
Number of Observations 9598 3250 6125 1534
Notes:
1.) Hazard Ratios for not surviving at 36 months reported with clustered standard errors.
2.) Significance: * (P,0.10), ** (P,0.05), *** (P,0.01).
3.) ‘‘SES’’- Socio-economic status.
doi:10.1371/journal.pone.0106456.t002
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When controlled for age and clinical factors i.e. stage and grade,
the effect of healthcare provider was diminished but remained
statistically significant for the entire follow-up period (HR: 0.608;
95% CI: 0.573, 0.644). Over a 36 month follow-up a 42% reduced
hazard of death was observed (HR: 0.577; 95% CI: 0.530, 0.628),
and a 37% reduced hazard was observed at 84 months (HR:
0.628; CI: 0.581, 0.679).
Results from the stratified, interaction Cox regression models
for non-proportional hazards are presented on Tables 2 and 3.
Over both follow-up times, a significant role accorded to socio-
economic status was evidenced when stratified by non-need factors
i.e. healthcare provider, marital status and region of residence.
Patients treated in a public setting from the lowest socio-economic
group had a 21% (P,0.01) increased hazard of death over the 36
month follow-up and a 25% (P,0.01) increased hazard of death
over the 84 month follow-up compared to those from the highest
socio-economic group. However, patients treated in part or wholly
in a private setting exhibited no social gradient for either follow-up
time in the non-proportional hazard models.
A social gradient in risk of death was also apparent for the
Gleason grade (5–7, .7) and clinical stage (II, III) strata; those
from lower socio-economic groups had a higher risk of mortality
across both follow-up time periods. Patients from the lowest socio-
economic group (SES5) with Gleason grade 5–7, and .7 had a
58% (P,0.01) and a 30% (P,0.01) increased risk of death,
respectively compared to the highest socio-economic group, over
the 84 month follow-up period. The same patterns were seen in
the analysis of the entire follow-up available (data not shown).
Results of the logistic regression analyses of risk of death are
reported in Table 4, for the three periods of follow-up (all, 36
months, 84 months). In the logistic models, healthcare provider
was not statistically significant when a wider range of covariates
were controlled for. However, there was a significant interaction
between healthcare provider and age: those aged 70 and over
(representing approximately 50% of the study cohort) treated in
Table 3. Multivariate stratified Cox regression for 84 month survival.
Stratified interaction non-PH Cox regression Model (84 month follow-up)
Private Public Married Not Married
SES1 1 1 1 1
SES2 1.15 1.24*** 1.34*** 1.19*
SES3 0.94 1.07 1.12* 1.11
SES4 0.97 1.18*** 1.23*** 1.17**
SES5 1.09 1.25*** 1.39*** 1.22***
SES Unknown 0.81 1.21*** 1.16* 1.16
Global Test 2.22 (P = 0.82) 3.26 (P = 0.66) 6.29 (P = 0.28) 6.72 (P = 0.24)
Wald Test *SES group Chi2(5) = 6.73 (P = 0.24) Chi2(5) = 24.17 (P = 0.00) Chi2(5) = 38.83 (P = 0.00) Chi2(5) = 8.36 (P = 0.13)
Number of Observations 2902 7408 6875 3435
Gleason grade 5–7 Gleason grade .7 Stage II Stage III
SES1 1 1 1 1
SES2 1.38*** 1.25** 1.48*** 1.64*
SES3 1.21** 1.05 1.28** 1.58*
SES4 1.19** 1.28*** 1.27** 1.62**
SES5 1.58*** 1.30*** 1.50*** 1.83***
SES Unknown 1.24* 1.15 1.24* 0.93
Global Test 4.29 (P = 0.49) 2.13 (P = 0.83) 4.56 (P = 0.47) 4.94 (P = 0.42)
Wald Test *SES group Chi2(5) = 38.67 (P = 0.00) Chi2(5) = 13.92 (P = 0.02) Chi2(5) = 24.84 (P = 0.00) Chi2(5) = 10.43 (P = 0.06)
Number of Observations 4753 2041 4119 748
Leinster Connacht Munster Ulster
SES1 1 1 1 1
SES2 1.35*** 1.47** 1.06 0.80
SES3 1.15* 1.23 0.93 0.97
SES4 1.26*** 1.35** 1.03 0.97
SES5 1.59*** 1.31* 1.10 0.86
SES Unknown 1.28** 1.18 1.08 0.59
Global Test 0.78 (P = 0.97) 4.47 (P = 0.48) 2.45 (0.78) 5.59 (P = 0.35)
Wald Test *SES group Chi2(5) = 61.31 P = 0.00) Chi2(5) = 7.96 (P = 0.15) Chi2(5) = 4.81 (P = 0.44) Chi2(5) = 4.24 (P = 0.51)
Number of Observations 4901 1458 3118 833
Notes:
1.) Hazard Ratios for not surviving at 36 months reported with clustered standard errors.
2.) Significance: * (P,0.10), ** (P,0.05), *** (P,0.01).
3.) ‘‘SES’’- Socio-economic status.
doi:10.1371/journal.pone.0106456.t003
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part or wholly in a private setting were 46% (P,0.01) overall, 49%
(P,0.01) at 36 months post-diagnosis and 52% (P,0.01) at 84
months post-diagnosis less likely to die compared to the those
under 70 years of age and treated solely in a public setting over the
respective follow-up periods. The logistic analyses also highlighted
a social gradient with patients from the lowest socio-economic
group being 26% (P,0.01) more likely to die at 36 months post-
diagnosis and 34% (P,0.01) more likely to die at 84 months post-
Table 4. Multivariate logistic regression analysis (odds ratios reported).
Logistic analyses at 36 months & 84 months follow-up
Dependant: Deceased at date of censoring= 1 and 0 otherwise Overall 36+ months 84+ months
Health provider: Public 1 1 1
Private/Mixed 0.94 (CI:0.64, 1.36) 0.93 (CI:0.64, 1.36) 1.04 (CI: 0.57, 1.90)
Age: 35–54 years 1 1 1
55–69 years 2.06*** (CI:1.62, 2.62) 2.01*** (CI: 1.53, 2.64) 2.08*** (CI:1.34, 3.25)
70 and over years 9.08*** (CI:7.01, 11.74) 9.23*** (CI: 6.86, 12.42) 11.26*** (CI:7.05, 17.96)
Interactions: 55–69 years/Private 0.77 (CI: 0.55, 1.10) 0.73* (CI:0.51, 1.05) 0.66 (CI:0.37, 1.17)
70 years and over/Private 0.54*** (CI:0.39, 0.76) 0.51*** (CI:0.37, 0.72) 0.48*** (CI:0.28, 0.82)
Socio-economic status: SES1 1 1 1
SES2 1.17*** (CI:1.05, 1.30) 1.22*** (CI:1.08, 1.37) 1.33*** (CI:1.15, 1.53)
SES3 1.12*** (CI:1.02, 1.24) 1.14** (CI:1.02, 1.27) 1.22*** (CI:1.08, 1.37)
SES4 1.08 (CI:0.97, 1.19) 1.10 (CI:0.97, 1.24) 1.19** (1.02, 1.39)
SES5 1.20*** (CI:1.09, 1.33) 1.26*** (CI:1.14, 1.39) 1.34*** (CI:1.18, 1.52)
SES Unknown 0.89 (CI:0.76, 1.05) 1.02 (CI:0.87, 1.19) 1.24** (CI:1.01, 1.53)
Stage: Stage I 1 1 1
Stage II 1.21 (CI:0.94, 1.55) 1.23 (CI:0.95, 1.59) 1.13 (CI:0.81, 1.58)
Stage III 1.28 (CI:0.93, 1.78) 1.35* (CI:0.98, 1.85) 1.30 (CI:0.93, 1.82)
Stage IV 9.37*** (CI:7.16, 12.26) 9.83*** (CI:7.61, 12.70) 7.94*** (CI:6.30, 10.02)
Stage Unknown 3.21*** (CI:2.42, 4.27) 2.88*** (CI:2.13, 3.88) 1.95*** (CI:1.56, 2.43)
Grade: Gleason ,5 1 1 1
Gleason 5–7 0.70*** (0.60, 0.83) 0.73*** (CI:0.62, 0.86) 0.87* (CI:0.76, 1.01)
Gleason .7 1.48** (CI:1.08, 2.04) 1.85*** (CI:1.50, 2.29) 2.47*** (CI:2.06, 2.94)
Grade Undifferentiated 2.13*** (CI:1.20, 3.76) 2.87*** (CI:1.46, 5.65) 3.50** (CI:1.03, 11.90)
Gleason grade Unknown 1.96*** (CI:1.53, 2.50) 2.10*** (1.70, 2.60) 2.21*** (CI:2.00, 2.44)
Marital Status: Single/Divorced/Widowed 1 1 1
Married 0.80*** (CI:0.71, 0.91) 0.75*** (CI:0.68, 0.82) 0.71*** (CI:0.64, 0.79)
Region: Leinster 1 1 1
Ulster 0.55*** (CI:0.45, 0.66) 0.54*** (0.43, 0.69) 0.56*** (0.43, 0.73)
Connacht 0.83*** (CI:0.72, 0.96) 0.87** (0.76, 0.99) 0.87 (0.68, 1.13)
Munster 1.31*** (CI:1.20, 1.42) 1.30*** (1.18, 1.43) 1.16*** (1.08, 1.24)
MOP: Other 1 1 1
Screen- opportunistic 0.39*** (0.26, 0.58) 0.37*** (CI:0.25, 0.57) 0.47*** (CI:0.29, 0.77)
Incidental 1.08 (CI:0.85, 1.38) 0.95 (CI:0.76, 1.18) 0.83*** (CI:0.74, 0.93)
Symptomatic 1.59*** (CI:1.17, 2.17) 1.37*** (CI:1.13, 1.67) 1.28*** (CI:1.18, 1.40)
Smoker at diagnosis: No 1 1 1
Yes 1.73*** (CI:1.59, 1.89) 1.64*** (CI:1.52, 1.77) 1.63*** (CI:1.43, 1.86)
Number of Obs 26816 21054 10697
Wald test for Stage and Gleason Grade Chi2 (8) = 1640 (P = 0.00) Chi2 (8) = 41488 (P = 0.00) Chi2 (5) = 1427 (P = 0.00)
Wald test for SES & Region Chi2 (8) = 850 (P = 0.00) Chi2 (8) = 3162 (P = 0.00) Chi2 (5) = 93.91 (P = 0.00)
% Correctly Classified 79.80% 78.22% 76.37%
Notes:
1.) Odds Ratios with clustered standard errors (Confidence Intervals in brackets).
2.) Significance: * (P,0.10), ** (P,0.05), *** (P,0.01).
3.) ‘‘SES’’- Socio-economic status.
4.) Interactions between socio-economic status and healthcare provider were also included in the logistic analyses but not reported above due to lack of statistical
significance across all models.
doi:10.1371/journal.pone.0106456.t004
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diagnosis compared to the highest socio-economic group; thus
confirming the presence of socio-economic inequality when a
wider range of confounding factors were controlled for. When
interaction terms for socio-economic status and healthcare
provider (private) were also included in logistic models (results
not shown), no statistically significant impact on mortality was
evident for this term. That an effect was detected in the Cox but
not logistic models may reflect the greater sensitivity of a model
using time to event rather than event within a defined time in this
particular case. A further set of logistic analyses was undertaken
stratifying by healthcare status highlighted in Table 5; in the 84
month post-diagnosis follow-up, those with access to private care
from the lowest socio-economic group were 28% (P,0.01) more
likely to die than those from the highest socio-economic group;
among those with access to public healthcare only, those from the
lowest socio-economic group were 33% (P,0.01) more likely to
die than those from the highest socio-economic group.
Table 5. Multivariate logistic regression analysis stratified by healthcare payer (odds ratios reported).
Stratified logistic analysis at 84 months follow-up
Dependant: Deceased at date of censoring= 1 and 0 otherwise Private = 1 Private = 0
Age: 35–54 years 1 1
55–69 years 1.37 (CI:0.68, 2.79) 2.05*** (CI:1.33, 3.15)
70 and over years 5.76*** (CI:3.47, 9.57) 10.82*** (CI:6.88, 17.00)
Socio-economic status: SES1 1 1
SES2 1.21 (CI:0.88, 1.66) 1.31*** (CI:1.14, 1.50)
SES3 1.07 (CI:0.77, 1.50) 1.21*** (CI:1.07, 1.37)
SES4 1.22*** (CI:1.07, 1.39) 1.18** (1.01, 1.37)
SES5 1.28*** (CI:1.04, 1.57) 1.33*** (CI:1.15, 1.52)
SES Unknown 1.04 (CI:0.80, 1.35) 1.21* (CI:0.97, 1.52)
Stage: Stage I 1 1
Stage II 0.58** (CI:0.36, 0.92) 1.34 (CI:0.93, 1.96)
Stage III 0.59** (CI:0.37, 0.93) 1.64*** (CI:1.16, 2.31)
Stage IV 5.30*** (CI:3.97, 7.08) 8.67*** (CI:6.42, 11.72)
Stage Unknown 0.89 (CI:0.67, 1.19) 2.42*** (CI:1.85, 3.18)
Grade: Gleason ,5 1 1
Gleason 5–7 0.99 (0.83, 1.17) 0.84* (CI:0.68, 1.03)
Gleason .7 3.45*** (CI:2.10, 5.65) 2.07*** (CI:1.64, 2.59)
Grade Undifferentiated 12.82 (CI:0.57, 285.86) 2.68* (CI:0.86, 8.33)
Gleason grade Unknown 1.46*** (CI:1.08, 1.98) 2.39*** (CI:2.17, 2.63)
Marital Status: Single/Divorced/Widowed 1 1
Married 0.83** (CI:0.69, 1.00) 0.68*** (CI:0.62, 0.75)
Region: Leinster 1 1
Ulster 0.61*** (CI:0.46, 0.83) 0.54*** (0.40, 0.73)
Connacht 0.77 (CI:0.46, 1.27) 0.93 (0.72, 1.20)
Munster 0.90 (CI:0.70, 1.17) 1.22** (1.02, 1.46)
MOP: Other 1 1
Screen- opportunistic 0.77 (0.53, 1.13) 0.42*** (CI:0.24, 0.74)
Incidental 0.86 (CI:0.65, 1.14) 0.84*** (CI:0.74, 0.95)
Symptomatic 1.36*** (CI:1.18, 2.10) 1.29*** (CI:1.20, 1.40)
Smoker at diagnosis: No 1 1
Yes 1.58*** (CI:1.19, 1.56) 1.65*** (CI:1.45, 1.87)
Number of Obs 2917 7780
Wald test for Stage and Gleason Grade Chi2 (5) = 128 (P = 0.00) Chi2 (5) = 868 (P = 0.00)
Wald test for SES & Region Chi2 (5) = 11 (P = 0.05) Chi2 (5) = 78 (P = 0.00)
% Correctly Classified 74.87% 77.07%
Notes:
1.) Odds Ratios with clustered standard errors (Confidence Intervals in brackets).
2.) Significance: * (P,0.10), ** (P,0.05), *** (P,0.01).
3.) ‘‘SES’’- Socio-economic status.
doi:10.1371/journal.pone.0106456.t005
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Discussion
Variations in survival after a diagnosis of cancer have attracted
increased attention by researchers. The analyses carried out here
highlights that patients treated in a private healthcare setting had
an average of 40% reduced risk of mortality compared to those
who were treated solely in the public setting, when adjusted for age
and clinical variables. It is also evident from these results that, after
controlling for stage, grade, marital status, healthcare setting and
region of residence, there was a clear socio-economic gradient in
survival. Moreover, socio-economic status and healthcare provider
interacted to influence risk of mortality in proportional hazard
models. Patients who accessed public healthcare provision from
the lowest socio-economic group had approximately 21–25%
increased risk of death compared to those from the highest socio-
economic group; this gradient was not evident for patients who
were seen by a private provider when addressing time dependen-
cy. Care, however, is warranted in the interpretation of this result.
A number of studies have examined the relationship between
health insurance status and cancer service utilization in Ireland
and internationally [13,30–32]. The evidence here relates to
where patients were treated rather than insurance status directly
and is open to different interpretations. While it is possible that
there exist differences in the quality of care provided in the public
and private systems that directly impacts upon survival, it must be
remembered that the mortality examined here is all-cause
mortality. Consequently it is also possible that the differences in
survival observed between patients treated in public and private
healthcare settings relate more to differences in patient character-
istics than the care received in respect of prostate cancer.
While we adjusted for a range of clinical and socio-demographic
factors, we were not able to adjust for many other factors that may
differ between public and privately-treated patients and that may
affect survival. These could include, for example, PSA level at
diagnosis, patient preferences, functional and health status, and
various other health-related and non-health-related (e.g. availabil-
ity of social support) indicators of suitability for curative treatment.
Moreover, selection effects may exist in terms of lifestyle between
those who consume care in private and public facilities; the former
may have unobserved healthier behaviours that can explain
differences in survival, independent of the care received. As noted
the need for caution here is acute given the use of all-cause
mortality in this study; those dying with prostate cancer rather
than from prostate cancer may exhibit unique clinical and
environmental characteristics that could not be controlled for in
this analysis [6].
This analysis had several limitations. Firstly, the analysis
examined all-cause mortality due to lack of availability of
patient-level information on cause of death; as stated above
caution is necessary in interpretation, however previous analyses
have found marginal survival differences in all-cause and excess
mortality in prostate cancer [33]. In addition, data were not
available on co-morbidities and therefore this could not be
controlled for; those from lower socio-economic groups tradition-
ally have higher co-morbidities than those from higher socio-
economic groups which may partly explain the social gradient
evidenced [34]. However, a recent study investigating confound-
ing factors in curative treatments for prostate cancer patients in the
RoI found no significant role accorded to co-morbidities [35]. The
categorical variables for stage, grade and socio-economic status all
contained an ‘unknown’ category which was included in the
analysis for purposes of completeness. It was assumed based on
cross-tabulations with both clinical and non-need factors that each
of these ‘unknown’ categories exhibited a moderate ordering with
respect to their defined counterparts. This assumption was given
more weight when output from the various regression models was
examined. Finally, as discussed, the available data did not permit
breakdown of those cared for within the public system by whether
they were seen as private or public patients.
As increasing numbers of patients survive cancer, interest in
differences in survival patterns will increase. Given the high
incidence of prostate cancer in the RoI and internationally, a
better understanding of the determinants of survival will provide
policy makers and healthcare professionals with much needed
evidence to improve both access to and delivery of care. In this
analysis, a socio-economic gradient was evident, but the magni-
tude of the effect varied considerably dependent upon the sub
groups analysed as well as the follow-up time periods. The results
with respect to healthcare provision may give rise to concerns but
care is warranted in the interpretation and further analysis of them
required to establish whether concerns are legitimate or misplaced.
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